Abstract

In type 1 diabetes management, the availability of algorithms capable of accurately forecasting future blood glucose (BG) concentrations and hypoglycemic episodes could enable proactive therapeutic actions, e.g., the consumption of carbohydrates to mitigate, or even avoid, an impending critical event. The only input of this kind of algorithm is often continuous glucose monitoring (CGM) sensor data, because other signals (such as injected insulin, ingested carbs, and physical activity) are frequently unavailable. Several predictive algorithms fed by CGM data only have been proposed in the literature, but they were assessed using datasets originated by different experimental protocols, making a comparison of their relative merits difficult. The aim of the present work was to perform a head-to-head comparison of thirty different linear and nonlinear predictive algorithms using the same dataset, given by 124 CGM traces collected over 10 days with the newest Dexcom G6 sensor available on the market and considering a 30-min prediction horizon. We considered the state-of-the art methods, investigating, in particular, linear black-box methods (autoregressive; autoregressive moving-average; and autoregressive integrated moving-average, ARIMA) and nonlinear machine-learning methods (support vector regression, SVR; regression random forest; feed-forward neural network, fNN; and long short-term memory neural network). For each method, the prediction accuracy and hypoglycemia detection capabilities were assessed using either population or individualized model parameters. As far as prediction accuracy is concerned, the results show that the best linear algorithm (individualized ARIMA) provides accuracy comparable to that of the best nonlinear algorithm (individualized fNN), with root mean square errors of 22.15 and 21.52 mg/dL, respectively. As far as hypoglycemia detection is concerned, the best linear algorithm (individualized ARIMA) provided precision = 64%, recall = 82%, and one false alarm/day, comparable to the best nonlinear technique (population SVR): precision = 63%, recall = 69%, and 0.5 false alarms/day. In general, the head-to-head comparison of the thirty algorithms fed by CGM data only made using a wide dataset shows that individualized linear models are more effective than population ones, while no significant advantages seem to emerge when employing nonlinear methodologies.

Highlights

  • Type 1 diabetes (T1D) is a metabolic disease characterized by an autoimmune destruction of the pancreatic cells responsible for insulin production and compromises the complex physiological feedback systems regulating blood glucose (BG) homeostasis

  • The root mean square error (RMSE) achieved with the population autoregressive moving average (ARMA) and autoregressive integrated moving average (ARIMA) were, respectively, about 23.75 and

  • The forecasting of future glucose levels and/or hypoglycemic episodes has the potential to play a key role in improving diabetes management

Read more

Summary

Introduction

Type 1 diabetes (T1D) is a metabolic disease characterized by an autoimmune destruction of the pancreatic cells responsible for insulin production and compromises the complex physiological feedback systems regulating blood glucose (BG) homeostasis.As a consequence, T1D people are requested to keep their glycemia within a safe range (i.e., BG of 70–180 mg/dL). The management of T1D therapy, which is mainly based on exogenous insulin infusions, requires the frequent monitoring of BG concentrations. Today, such monitoring is performed using continuous glucose monitoring (CGM) sensors, which allow collecting and visualizing glucose concentrations almost continuously (e.g., every 5 min) for several days [1,2]. All commercial CGM devices are labeled as minimally invasive since they require either a microneedle or a small capsule to be inserted in the subcutis, and they represent an important innovation because they allow reducing the burden of performing multiple daily invasive self-monitoring tests of BG concentrations. Noninvasive CGM devices represent a further step in reducing the burden related to the daily management of T1D, but they are all still prototypes

Objectives
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call